| Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia. | |
| | |
MedLine Citation:
|
PMID: 20667972 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Angiotensin I-converting enzyme (ACE; kininase II) levels in humans are genetically determined. ACE levels have been linked to risk of myocardial infarction, but the association has been inconsistent, and the causality underlying it remains undocumented. We tested the hypothesis that genetic variation in ACE levels influences myocardial tolerance to ischemia. We studied ischemia-reperfusion injury in mice bearing 1 (ACE1c), 2 (ACE2c, wild type), or 3 (ACE3c) functional copies of the ACE gene and displaying an ACE level range similar to humans. Infarct size in ACE1c was 29% lower than in ACE2c (P<0.05). Pretreatment with a kinin B2 receptor antagonist suppressed this reduction. In ACE3c, infarct size was the same as in ACE2c. But ischemic preconditioning, which reduced infarct size in ACE2c (-63%, P<0.001) and ACE1c (-52%, P<0.05), was not efficient in ACE3c (-2%, NS, P<0.01 vs. ACE2c). In ACE3c, ischemic preconditioning did not decrease myocardial inflammation or cardiomyocyte apoptosis. Pretreatment with a renin inhibitor had no cardioprotective effect in ACE2c, but in ACE3c partially restored (38%) the cardioprotection of ischemic preconditioning. Thus, a modest genetic increase in ACE impairs myocardial tolerance to ischemia. ACE level plays a critical role in cardiac ischemia, through both kinin and angiotensin mediated mechanisms. |
| | |
Authors:
|
Erij Messadi; Marie-Pascale Vincent; Violaine Griol-Charhbili; Chantal Mandet; Juliana Colucci; John H Krege; Patrick Bruneval; Nadine Bouby; Oliver Smithies; François Alhenc-Gelas; Christine Richer |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-07-28 |
Journal Detail:
|
Title: FASEB journal : official publication of the Federation of American Societies for Experimental Biology Volume: 24 ISSN: 1530-6860 ISO Abbreviation: FASEB J. Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-12-02 Completed Date: 2011-01-04 Revised Date: 2013-04-11 |
Medline Journal Info:
|
Nlm Unique ID: 8804484 Medline TA: FASEB J Country: United States |
Other Details:
|
Languages: eng Pagination: 4691-700 Citation Subset: IM |
Affiliation:
|
INSERM U872, Centre de Recherche des Cordeliers, Paris, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Amides
/
pharmacology Angiotensin I / pharmacology Angiotensin II / pharmacology Animals Apoptosis / drug effects Blood Pressure / drug effects Bradykinin / analogs & derivatives, pharmacology Fumarates / pharmacology Heart / drug effects* Kinins / pharmacology Lung / enzymology Mice Mice, Mutant Strains Myocardial Infarction / enzymology*, genetics Myocardial Ischemia / enzymology*, genetics Myocardium / enzymology* Peptidyl-Dipeptidase A / genetics, metabolism* Receptors, Bradykinin / antagonists & inhibitors Renin / antagonists & inhibitors Reperfusion Injury / genetics* |
| Grant Support | |
ID/Acronym/Agency:
|
R01 HL049277/HL/NHLBI NIH HHS; R01 HL049277-16/HL/NHLBI NIH HHS; R01 HL049277-17/HL/NHLBI NIH HHS; R01 HL049277-18/HL/NHLBI NIH HHS; R01 HL049277-19/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Amides; 0/Fumarates; 0/Kinins; 0/Receptors, Bradykinin; 11128-99-7/Angiotensin II; 502FWN4Q32/aliskiren; 58-82-2/Bradykinin; 7PG89G35Q7/icatibant; 9041-90-1/Angiotensin I; EC 3.4.15.1/Peptidyl-Dipeptidase A; EC 3.4.23.15/Renin |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/...
Next Document: Protective role of the leukotriene B4 receptor BLT2 in murine inflammatory colitis.